For patients with diabetes, exposure to GLP-1 RAs associated with increased risk for incident neovascular age-related macular degeneration.

Sociodemographic disparities, such as low income and lack of health insurance, contribute to reduced CRC screening at age 45 years.

The FDA has approved Starjemza (ustekinumab-hmny), a biosimilar to Stelara (ustekinumab), for the treatment of various chronic inflammatory diseases.

Ambulatory acute kidney injury is common among individuals with cirrhosis and is associated with a high 90-day mortality.

Early-life factors are associated with body mass index trajectories in children, with risk for obesity detectable at age 3.5 years.

The FDA has accepted for review the NDA for linerixibat for the treatment of cholestatic pruritus in patients with primary biliary cholangitis.

Experienced weight stigma improves from pre- to post-metabolic bariatric surgery, according to a recent study.

Growth hormone was not associated with a lower risk for the composite liver outcome among patients with adult-onset craniopharyngioma.

More than one-third of patients with SSc screened positive for self-reported depression, with GI involvement identified as the most significant predictor.

In a retrospective study, overlapping biologic therapy for ulcerative colitis or Crohn disease did not significantly increase risk of infections.

Individuals with IBD, especially CD, have an increased risk for myocardial infarction, ischemic heart disease, cerebrovascular accident, and major adverse cardiovascular events.

Waist-to-height ratio had a better predictive value than BMI in assessing liver fibrosis and steatosis outcomes across ages and racial groups.